Back to News
Market Impact: 0.35

3 Unstoppable Defense Stocks on the Pentagon's Short List

LMTPLTRNVDAAAPLNFLX
Infrastructure & DefenseFiscal Policy & BudgetGeopolitics & WarTechnology & InnovationCompany FundamentalsAnalyst Insights

The article highlights a potential step-up in U.S. defense spending, with the initial 2027 defense budget proposal at $1.5 trillion versus $1 trillion in 2026, including major space and missile-defense programs. Rocket Lab won an $816 million satellite contract but is viewed as expensive at 65x sales; Lockheed Martin is framed as a steadier, cheaper contractor at 20x forward earnings and 1.9x sales; Palantir remains a high-growth but highly valued name at 81.5x sales. Overall message is selective optimism on defense exposure, but with caution on valuations.

Analysis

The market is starting to treat defense as a multi-year capacity build, not a cyclical procurement tape. The second-order winner is less the headline platform vendors and more the firms that can compress delivery timelines, clear security hurdles, and bundle hardware with software or services; that favors vertical integration and recurring support revenue over pure launch or pure analytics exposure. In practice, that means the real upside should accrue to contractors that can turn one award into a backlog flywheel, while the weakest links are suppliers with bottlenecks in propulsion, sensors, secure compute, and launch infrastructure. Valuation is the critical differentiator: the market is paying growth-stock multiples for defense optionality, which leaves little room for execution slippage. The premium names are now hostage to budget conversion speed, not just geopolitical headlines; if appropriations lag, contract announcements will not be enough to justify current multiples. By contrast, the lower-multiple incumbent offers a cleaner risk-adjusted way to own the same macro theme because it can absorb program mix shifts and still compound earnings through share repurchase and backlog visibility. A contrarian angle is that the market may be overestimating how quickly experimental defense spend converts into durable revenue for newer entrants. These programs tend to face milestone delays, cost overruns, and integration risk, which can create a six- to twelve-month disconnect between contract wins and cash flow. The highest probability setup is therefore a relative-value trade: own the cash-generating incumbent while waiting for the high-multiple disruptors to de-rate or prove operating leverage over multiple quarters.